Vycor Medical Inc
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive co… Read more
Vycor Medical Inc (VYCO) - Net Assets
Latest net assets as of September 2025: $-4.02 Million USD
Based on the latest financial reports, Vycor Medical Inc (VYCO) has net assets worth $-4.02 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($941.20K) and total liabilities ($4.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.02 Million |
| % of Total Assets | -427.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -422.07% |
| Growth Volatility | 454.14 |
Vycor Medical Inc - Net Assets Trend (2012–2024)
This chart illustrates how Vycor Medical Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vycor Medical Inc (2012–2024)
The table below shows the annual net assets of Vycor Medical Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-3.69 Million | -10.96% |
| 2023-12-31 | $-3.33 Million | -13.08% |
| 2022-12-31 | $-2.94 Million | -22.78% |
| 2021-12-31 | $-2.40 Million | -20.89% |
| 2020-12-31 | $-1.98 Million | -46.28% |
| 2019-12-31 | $-1.35 Million | -76.17% |
| 2018-12-31 | $-768.83K | -1044.02% |
| 2017-12-31 | $81.44K | +408.05% |
| 2016-12-31 | $-26.44K | -102.31% |
| 2015-12-31 | $1.15 Million | -60.34% |
| 2014-12-31 | $2.89 Million | +187.15% |
| 2013-12-31 | $-3.31 Million | -127.37% |
| 2012-12-31 | $-1.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vycor Medical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1216994200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $29.56 Million | % |
| Total Equity | $-3.69 Million | 100.00% |
Vycor Medical Inc Competitors by Market Cap
The table below lists competitors of Vycor Medical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CREALOGIX HLDG N
MU:CX1
|
$844.13K |
|
Century Global Commodities Corp
PINK:CEUMF
|
$844.53K |
|
CASELLA WASTE SYS-A
BE:WA3
|
$844.54K |
|
KAWASAKI HEAVY IND - Dusseldorf Stock Exchang
DU:KHE
|
$844.70K |
|
LABOCANNA S.A. ZY-10
F:9Y2
|
$843.90K |
|
PolyPlank publ AB
ST:POLY
|
$843.62K |
|
AB Linas
MU:YCJ
|
$842.92K |
|
WYNN RESORTS - Dusseldorf Stock Exchang
DU:WYR
|
$842.27K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vycor Medical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -3,325,476 to -3,690,083, a change of -364,607.
- Net loss of 107,200 reduced equity.
- Other factors decreased equity by 257,407.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-107.20K | -2.91% |
| Other Changes | $-257.41K | -6.98% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Vycor Medical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.00 | $0.07 | x |
| 2018-12-31 | $-0.03 | $0.07 | x |
| 2019-12-31 | $-0.05 | $0.07 | x |
| 2020-12-31 | $-0.07 | $0.07 | x |
| 2021-12-31 | $-0.08 | $0.07 | x |
| 2022-12-31 | $-0.09 | $0.07 | x |
| 2023-12-31 | $-0.10 | $0.07 | x |
| 2024-12-31 | $-0.11 | $0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vycor Medical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.75%
- • Asset Turnover: 1.59x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-194.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -140.18% | -323.98% | 0.33x | 1.32x | $-4.34 Million |
| 2015 | -181.78% | -182.91% | 0.56x | 1.77x | $-2.20 Million |
| 2016 | 0.00% | -113.74% | 0.98x | 0.00x | $-1.65 Million |
| 2017 | -1813.62% | -106.65% | 0.96x | 17.80x | $-1.49 Million |
| 2018 | 0.00% | -91.39% | 1.45x | 0.00x | $-1.30 Million |
| 2019 | 0.00% | -53.73% | 1.36x | 0.00x | $-660.76K |
| 2020 | 0.00% | -72.02% | 1.16x | 0.00x | $-624.35K |
| 2021 | 0.00% | -31.28% | 1.49x | 0.00x | $-196.14K |
| 2022 | 0.00% | -33.11% | 1.42x | 0.00x | $-110.83K |
| 2023 | 0.00% | -4.77% | 1.47x | 0.00x | $262.86K |
| 2024 | 0.00% | -6.75% | 1.59x | 0.00x | $261.81K |
Industry Comparison
This section compares Vycor Medical Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vycor Medical Inc (VYCO) | $-4.02 Million | -140.18% | N/A | $843.92K |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |